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Abstract
Background: The prevalence and the patterns of ocular inflammatory disease and ocular tuberculosis (TB) are
largely undocumented among Multidrug Resistant TB (MDR-TB) patients co-infected with Human
Immunodeficiency Virus (HIV) and on antituberculosis and antiretroviral therapy (ART).
Methods: Lilavati Hospital and Research Center and Médecins Sans Frontières (MSF) organized a cross-sectional
ophthalmological evaluation of HIV/MDR-TB co-infected patients followed in an MSF-run HIV-clinic in Mumbai, India,
which included measuring visual acuity, and slit lamp and dilated fundus examinations.
Results: Between February and April 2012, 47 HIV/MDR-TB co-infected patients (including three patients with
extensively drug-resistant TB) were evaluated. Sixty-four per cent were male, mean age was 39 years (standard
deviation: 8.7) and their median (IQR) CD4 count at the time of evaluation was 264 cells/μL (158–361). Thirteen
patients (27%) had detectable levels of HIV viremia (>20 copies/ml). Overall, examination of the anterior segments
was normal in 45/47 patients (96%). A dilated fundus examination revealed active ocular inflammatory disease in
seven eyes of seven patients (15.5%, 95% Confidence Intervals (CI); 5.1-25.8%). ‘These included five eyes of five
patients (10%) with choroidal tubercles, one eye of one patient (2%) with presumed tubercular chorioretinitis and
one eye of one patient (2%) with evidence of presumed active CMV retinitis. Presumed ocular tuberculosis was thus
seen in a total of six patients (12.7%, 95% CI; 3.2-22.2%). Two patients who had completed anti-TB treatment had
active ocular inflammatory disease, in the form of choroidal tubercles (two eyes of two patients). Inactive scars were
seen in three eyes of three patients (6%). Patients with extrapulmonary TB and patients <39 years old were at
significantly higher risk of having ocular TB [Risk Ratio: 13.65 (95% CI: 2.4-78.5) and 6.38 (95% CI: 1.05-38.8)
respectively].
Conclusions: Ocular inflammatory disease, mainly ocular tuberculosis, was common in a cohort of HIV/MDR-TB
co-infected patients in Mumbai, India. Ophthalmological examination should be routinely considered in HIV
patients diagnosed with or suspected to have MDR-TB, especially in those with extrapulmonary TB.
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Background
Ocular tuberculosis (OTB) results from the haematogen-
ous dissemination of mycobacteria and may affect virtually
any intraocular tissue. Clinical features depend on the spe-
cific tissue involved and may be due to both, direct tissue
infection or due to hypersensitivity reactions. The charac-
teristic findings include tubercles, tuberculomas and
serpiginous-like choroiditis. These represent direct chor-
oidal infection via the hematogenous route. Less common
lesions include lupus vulgaris of the eyelids, conjunctivitis,
corneal ulcers and phlyctenulosis, and scleritis. Neuro-
opthalmological lesions include orbital apex syndrome,
disc edema and sixth nerve palsies.
Non-invasive ocular examinations to detect ocular tu-
berculosis have several potential advantages. They may
suggest a diagnosis in a subset of patients, thus allowing
for a more focused investigational approach. This may
be more important in immunocompromised patients
who tend to have abnormal systemic findings (absence
of fever) or investigational findings (anergic mantoux
tests readings or unusual chest radiography). These find-
ings may delay a diagnosis of systemic tuberculosis with
the attendant risks of poor outcomes.
The association between systemic TB disease and ocu-
lar dissemination has been widely reported. The ocular
morbidity pattern in 2010 eyes of 1005 patients with ac-
tive pulmonary and extrapulmonary tuberculosis disease
was studied prospectively in India; 1.4% of patients had
ocular lesions [1]. In a study from Spain, Bouza et al. ex-
amined 100 patients with culture-positive tuberculosis
and found that 18 (18%) of patients had tubercular
choroiditis, papillitis, retinitis, and vitritis [2]. Eleven out
of these 18 patients were HIV-infected. Systemic dissem-
ination has also been reported to significantly increase
the likelihood of ocular lesions up to 60% [3].
It is unclear whether the dual HIV-TB epidemic has
lead to an increase in the prevalence and incidence of
ocular tuberculosis in patients with active TB disease
and co-infected with HIV. In various studies from
Africa, differing proportions of ocular tuberculosis in as-
sociation with HIV infection have been reported, varying
between 0 to 2.8%, depending on the size and clinical
characteristic of the studied cohort [4,5]. Opportunistic
ocular infections are rare in an African population, des-
pite the increasing availability of antiretroviral drugs
with its attendant reduction of morbidity and mortality.
In a prospective study from Mumbai, India, 23.5% of
AIDS patients with systemic tuberculosis had ocular le-
sions [6] but a much lower prevalence was seen in a
neighbouring city, where although as many as 66% of
1268 AIDS patients had systemic tuberculosis, only 1%
of patients had ocular TB [7]. Babu et al., in the largest
Indian cohort of referred HIV/AIDS patients (766) from
a tertiary care centre, described ocular tuberculosis in 19
eyes of 15 patients (2.0%). Clinical presentations in-
cluded choroidal granulomas in 10 eyes, subretinal
abscess in seven eyes (worsening to panophthalmitis in
three eyes), and conjunctival tuberculosis and pano-
phthalmitis each in one eye [8].
Multidrug-resistant tuberculosis (MDR-TB) is defined
as TB that is resistant to both isoniazid and rifampicin.
Extensively drug-resistant tuberculosis (XDR-TB) is de-
fined as MDR-TB with additional resistance to any
fluoroquinolone and to at least one of three injectable
second-line anti-tuberculosis drugs used in treatment
(capreomycin, kanamycin or amikacin).
To-date, no data are available on the overall preva-
lence or common presentations of ocular inflammatory
disease (OID), especially ocular tuberculosis, in patients
with MDR-TB including those co-infected with HIV.
The objectives of this study were 1) to assess the
prevalence and presentations of ocular inflammatory dis-
ease and ocular tuberculosis, in particular, in a cohort of
MDR-TB patients co-infected with HIV and 2) to iden-
tify possible risk factors for developing ocular tubercu-
losis, including those factors related to HIV infection
and to drug resistance.
Method
Ethics statement
The study was approved by the Institutional Review
Board of Lilavati Hospital & Research Center, Mumbai,
India and by the Médecins Sans Frontières independent
Ethics Review Board, Geneva, Switzerland. Patients were
counselled about the study and an informed consent was
obtained.
Study design
This was a cross-sectional study in a cohort of MDR-TB
patients co-infected with HIV receiving care and treat-
ment at an HIV clinic in Mumbai, India.
Setting and study population
Médecins Sans Frontières (MSF) has been operating an
HIV clinic in Mumbai since 2006 and has been treating
MDR-TB among HIV-infected individuals since May
2007. MDR-TB treatment became available in the public
sector in Mumbai only in late 2010. Patients received
empirical or when possible individualized therapy
through an ambulatory, community-based program that
we have described elsewhere [9]. In summary, an indi-
vidualized TB treatment regimen is designed for each
patient, based on the first and second line drug suscepti-
bility test (DST) results and on a patient’s treatment his-
tory. Patients are treated for at least 20 months, based
on WHO guidelines updated in 2011 [10]. For treatment
of HIV, first line antiretroviral therapy (ART) typically
consists of two nucleoside/tide reverse transcriptase
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inhibitors (NRTIs) and one non-nucleoside reverse tran-
scriptase inhibitor (NNRTI), while patients in need of
second line ART received a protease inhibitor-based
regimen along with NRTIs [11].
The study was conducted from February 2012 to April
2012. All MDR-TB patients co-infected with HIV who
were followed in the MSF clinic at the time of the study
were eligible to be included in the study, regardless if
they were on treatment during the study period or had
completed the treatment earlier. There were no exclu-
sion criteria for this study; only patients who died, were
lost to follow-up or were transferred out were not in-
cluded in the study.
Clinical evaluation protocol
Patients underwent a detailed clinical evaluation: pa-
tients were asked for systemic and ocular complaints, in-
cluding self-reported ones that may have been due to
antiretroviral and/or antituberculosis therapy. Systemic
evaluation was conducted as per the HIV clinic follow-
up protocol: this consisted of clinical assessment and
laboratory monitoring, including complete and differen-
tial blood counts, baseline hepatic and renal function
tests, HIV markers (subtype of infection, viral load and
CD4 counts), sputum collection on two consecutive days
or extrapulmonary biopsy (commonly lymph nodes) as
necessary. All collected samples underwent smear stud-
ies (with Ziehl Neelsen stain), culture and drug suscepti-
bility testing for first and second line anti-TB drugs
when culture was positive. Appropriate radiography was
also carried out.
Patients underwent a full ophthalmological evaluation
by a consultant ophthalmologist familiar with ocular com-
plications of HIV/AIDS, including visual acuity screening,
slit lamp examination and dilated fundus examination of
the entire retina in all patients using an indirect ophthal-
moscope. The presence and severity of ocular inflamma-
tory disease was assessed by documenting the presence,
grade and type of anterior uveitis, presence and grade of
vitreous cells (classified as grade 1, 2, 3 or 4), “snow-balls”,
and the presence of cystoid macular oedema (CME),
periphlebitis and intraocular pressure evaluation. We
followed the currently accepted SUN (standardized uveitis
nomenclature [12]) for the classification and grading of
the ocular inflammation. Fundus fluorescein angiography
or optical coherence tomography was done whenever
deemed necessary by the physician.
Data collection and analysis
Demographic and clinical information were systematic-
ally recorded in standardized clinical files. Information
on HIV and antiretroviral therapy was entered into a
specifically designed database. Data related to clinical
evaluation of eyes were entered in a specific simple
database. Data from all patients evaluated between
February 2012 and April 2012 were included in the ana-
lyses. Patient characteristics were summarized using
descriptive statistics. We used t-test, chi-square and
Fisher’s exact test to assess differences between variables,
as appropriate. Univariate and multivariate logistic re-
gression and generalized linear models (GLM) were fit-
ted to assess risk factors associated with the occurrence
of ocular TB. Factors and covariates used as predictors
included: age, sex, nadir CD4 count and CD4 count at
the time of evaluation, HIV viral load, tuberculosis site
(pulmonary/extrapulmonary), drug resistance pattern
(MDR/XDR) and time on antiretroviral and anti-Tb
treatment. We used the cohort’s mean age as a cut-off
point in the modelling. For the parameter estimation in
the generalized linear models we used the hybrid
method and a robust estimator. The Wald statistic was
used for the main analysis in the final model and the
Wald type for the 95% confidence intervals. A p-value of
less than 0.05 was considered to indicate statistical
significance. The computer software SPSS (IBM, SPSS,
Statistics, version 20) was used for analysis.
Results
Patient characteristics
A total of 51 patients were examined during the course of
this study. No patient refused consent to participate. Four
patients were excluded from the analyses; two HIV-
infected patients were found to have pan-susceptible TB
and two patients with MDR-TB were not HIV-infected,
but were followed in the HIV clinic because they were
household contacts of co-infected patients. Thus, forty-
seven patients were included in the analyses: 28 (59.6%)
males, 17(36.2%) females and two (4.2%) transgenders.
Ages ranged from 12 years to 54 years (mean 39 years,
SD: 8.7). The commonest subtype of HIV infection was
type HIV-1 (44, 93.6%) followed by HIV-2 (2, 4.2%) and
mixed HIV/1-2 infection (1, 2.1%). The median nadir
CD4-count and the median CD4-count at the time of the
evaluation were 153 cells/μL (IQR: 85–247) and 264 cells/
μL (IQR: 158–361) respectively. Thirteen patients (27%)
had detectable levels of HIV viremia (>20 copies/ml) at
the time of the evaluation. Fourteen patients (24.8%) had
been diagnosed with extrapulmonary TB (EPTB). The
drug resistance patterns included 44 patients (93.6%) with
multidrug resistance, and three patients (6.6%) with exten-
sive drug resistance. Patients were on antiretroviral treat-
ment for a median of 17.5 months (IQR: 4–32.5) and on
second-line anti-TB treatment for a median of 13 months
(IQR: 4–21) (Table 1).
Ocular inflammatory disease & ocular tuberculosis
Overall, examination of the anterior chamber was nor-
mal in 45/47 patients (96%). The examination of one
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patient (2%) showed a corneal opacity and one patient
(2%) had a well functioning bleb from prior glaucoma
surgery. Both patients were on ART and anti-TB treat-
ment at the time of the study. Among 36 patients on
ART and anti-TB treatment at the time of clinical evalu-
ation and among 11 patients who had completed anti-
TB treatment prior to the study, the examination of the
anterior chambers was normal in 34 patients (94.4%)
and in 11 patients (100%) respectively.
A dilated fundus examination revealed active or inactive
ocular inflammatory disease in seven eyes of seven pa-
tients (15.5%, 95% Confidence Intervals (CI): 5.1-25.8%).
These included five eyes of five patients (10.6%) with pre-
sumed choroidal tubercles (Additional file 1), three of
whom were still on anti-TB treatment. Presumed tubercu-
lar chorioretinitis and CMV retinitis was each seen in one
eye of one patient on treatment (2.1% respectively). Pre-
sumed ocular tuberculosis was thus seen in a total of six
patients (12.7%, 95% CI: 3.2% to 22.2%). Of note, two
patients who had completed anti-TB treatment had active
ocular inflammatory disease, in the form of choroidal
tubercles (two eyes of two patients).
Inactive scars were seen in three eyes of three patients
(6.3%): one scar in one eye of a patient on treatment and
two scars in two eyes of two patients who had com-
pleted treatment (one year and six months prior to this
evaluation respectively). Other pathology seen included
HIV retinopathy (two eyes of one patient, 2.1%) and sec-
ondary open angle glaucoma (one eye of one patient,
2.1%) not related to TB or HIV-infection. No cases of
multifocal choroidopathy, vasculitis, anterior uveitis,
intermediate uveitis or panuveitis were seen in the over-
all cohort. Table 2 summarizes the findings of the cross-
sectional evaluation.
Visual screening showed acuities ranging from 6/6 to
hand movements. Causes of visual loss included CMV
retinitis, presumed tubercular chorioretinitis, corneal
opacities and uncorrected refractive errors. All the
patients with choroidal tubercles were visually asymp-
tomatic whereas the patient with chorioretinitis had pro-
found visual loss due to the macular location of the
disease. No cases of elevated intraocular pressure were
found. One patient (2.1%) was on topical antiglaucoma
medication but the intraocular pressure was normal. We
found no patients with ocular adverse events due to
antiretroviral or antituberculosis drugs in this Mumbai
cohort as previously reported [13].
Risk factors for ocular tuberculosis
In univariate analyses, co-infected patients with
extrapulmonary tuberculosis or patients with both pul-
monary and extrapulmonary disease were eleven times
more at risk of ocular TB compared with those having
only pulmonary TB (risk ratio [RR] 11.62, 95% confi-
dence interval [CI] 1.96–68.87, Table 3). Age below 39
years was associated with a five-fold increase in the
prevalence of ocular TB, though this association was not
statistically significant. Increased immunosuppression, as
evidenced by the nadir CD4 T-cell count and CD4-
count at the time of the evaluation, was not associated
with heightened prevalence of ocular TB (Table 3). Gen-
der, HIV viremia and time on anti-TB treatment did not
show an association with ocular TB prevalence.
In multivariate analyses, extrapulmonary infection
remained the most important determinant of ocular TB
occurrence, i.e. with the greatest adjusted risk ratio
(aRR: 13.65, 95% CI: 2.4-78.5, p=0.003). The only other
Table 1 Patient characteristics (n=47)
Characteristic
Mean age (years) (SD) 39 (8.7)
Sex
Male, n (%) 30 (63.8)*
HIV infection & Antiretroviral treatment
Median nadir CD4 count (cells/μL) (IQR) 153
(85–247)




HIV viral load undetectable (<20 copies/μL) at
the time of evaluation, n (%)
34 (72.3)




Tuberculosis and anti-TB treatment
Multidrug-resistant TB (MDR-TB), n (%) 44 (93.6)
Extensively and extremely drug-resistant TB
(XDR & XXDR-TB), n (%)
3 (6.4)
Extra-pulmonary TB 14 (29.8)
Median duration of anti-TB treatment (months) (IQR) 13 (4–21)
* Two biological males were transgender.
Table 2 Ophthalmological examination findings among













Secondary open-angle glaucoma 1/1(2)
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factor independently associated with ocular TB was age
below 39 years (aRR: 6.38, 95% CI: 1.05-38.8, p=0.04).
The final multivariate model showed that immune status
and duration of anti-TB treatment were not associated
with the risk of ocular TB (Table 3).
Discussion
In this study we report rates of ocular inflammatory dis-
ease and presumed ocular tuberculosis from a cohort of
MDR-TB patients co-infected with HIV on antiretroviral
and anti-TB treatment. Despite India’s large burden of
MDR-TB and large absolute numbers of people living
with HIV, there are discouragingly few reports of experi-
ences with these patients [8,14,15]. To our knowledge
this is the first report on ocular disease from co-infected
patients in Asia and probably elsewhere.
We studied a relatively large cohort of HIV/MDR TB
co-infected patients and found a fairly high prevalence
of ocular inflammatory disease, commonest of which
was presumed ocular tuberculosis followed by CMV ret-
initis. Other commonly described ocular inflammatory/
infectious diseases in HIV infected patients such as
toxoplasmosis or other viral retinitis (presumed herpes
simplex/herpes zoster infections) were not seen in this
study, probably due to effective antiretroviral therapy.
In this Mumbai cohort, we observed a high yield of
ocular tuberculosis that is possibly due to the greater
propensity of HIV/AIDS patients to develop tubercu-
losis, along with the hyperendemic disease patterns of
tuberculosis seen in India. Patients who develop second-
ary MDR-TB (due to incorrect or inadequate regimens),
as well those who contract primary MDR-TB, are likely
to have a delay in diagnosis, with a corresponding
extended period of mycobacteraemia, that increases the
risk of ocular infection.
Our study reveals a higher prevalence of presumed
ocular tuberculosis than that reported by Biswas et al. in
a cohort of pulmonary tuberculosis patients in an era
where drug resistance was presumably far less common,
but less than that reported by Mehta et al. in a cohort of
HIV/TB patients [1,6]. Both these reports and other
similar studies did not address the issue of drug resist-
ance in enrolled patients and this remains an unknown
factor that does not permit accurate comparisons across
these studies. It is possible that an increasing prevalence
of drug-resistant tuberculosis, with or without HIV in-
fection, is causing a corresponding increase in the preva-
lence of ocular tuberculosis.
The commonest pattern of ocular inflammation en-
countered in this Mumbai cohort was choroidal tubercles
representing presumed choroidal tubercular infection,
followed by presumed tubercular chorioretinitis. Poster-
ior segment ocular tuberculosis in the form of multifocal
choroidopathy or vasculitis was not seen in this cohort.
Similarly, the classical patterns of granulomatous or non-
granulomatous anterior, intermediate or panuveitis were
not seen in any of the patients in our cohort. Our study
differs significantly from Babu et al. who noticed a lower
prevalence and a distinctly different clinical pattern. This
is probably because we studied all patients irrespective of
visual symptomatology, allowing us to detect asymptom-
atic patients having ocular tuberculosis without visual
morbidity. The large institutional cohort reported by
Babu and co-workers consisted of visually symptomatic
referrals to a large tertiary care center, often after a sig-
nificant delay.
Table 3 Univariate and multivariate analysis of risk factors for ocular tuberculosis among HIV/MDR-TB co-infected
patients (n=47)






Female 0.17 0.02- 1.51 0.11
Age, years >40 1 1
≤39 4.80 0.85-26.95 0.07 6.38 1.05-38.80 0.04
Nadir CD4-count ≤200 1
>200 0.65 0.13-3.21 0.60
CD4-count at evaluation ≤200 1 1
>200 0.59 0.10-3.35 0.55 0.21 0.18-2.52 0.21
HIV viral load at evaluation undetectable 1
detectable 1.18 0.20-6.75 0.85
Tuberculosis site pulmonary 1 1
extrapulmonary 11.62 1.96-68.87 0.007 13.65 2.37-78.53 0.003
Time on MDR-TB treatment (months) >6 1 1
≤6 0.53 0.09-2.99 0.47 0.39 0.03-4.79 0.46
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Earlier reports from the developed world suggested
mycobacterial ocular infections were much less com-
mon. In a study in 1987, tuberculosis was responsible
for 0.2% of cases of posterior uveitis and no cases of
anterior uveitis in Southern California [16]. Increasingly,
more recent reports are identifying a resurgence of
tuberculosis as the infecting organism in non-immuno-
compromised patients with ocular inflammatory disease.
In Italy, recent studies have described the clinical and in-
vestigational features of cohorts of 35 and 53 patients
[17,18]. In reports from Germany, PET/CT scan studies,
being the imaging modality of choice, were able to sug-
gest a tuberculous etiology in nine of 20 patients who
tested positive in a quantiferon gold test. Mycobacterium
tuberculosis was shown in cultures of lymph node biop-
sies in two patients. A good therapeutic response was
achieved in nine of 11 (82%) patients with anti-TB
therapy [19].
Among the risk factors we studied with univariate and
multivariate models, age and extrapulmonary tubercu-
losis were independently and significantly associated
with the occurrence of ocular TB. Widespread dissemin-
ation of mycobacterial infection, which is often seen in
patients with extrapulmonary tuberculosis, may explain
the higher risk for ocular TB possible risk factor. Inter-
estingly, in this cohort of co-infected patients, severe im-
munosuppression, as evidenced in the nadir CD4 T-cell
counts, was not associated with heightened prevalence
of ocular TB.
Findings suggestive of ocular tuberculosis were recorded
in two patients who had successfully completed their sec-
ond line anti-TB regimen. These two patients underwent
fluorescein angiography after an informed consent, and in-
creased hyperfluorescence was seen suggestive of active
intraocular inflammation. These patients, followed in our
HIV clinic, are currently in good health, and are being
closely monitored for the need for retreatment. Potentially,
the use of ocular evaluation, in these groups of patients,
may serve as a marker to monitor the therapeutic re-
sponse. Larger cohorts that assess the ongoing ocular re-
sponse of these patients may furnish data whether such
patients may be better served by non-standard treatment
regimens (therapeutic composition or duration) but such
data are currently not available.
There are some limitations to this study. First, the
study design was cross-sectional and the data were col-
lected from a cohort in a specific programmatic setting.
Our findings may not be applicable to other populations
with HIV/MDR-TB co-infection. Second, even though
this Mumbai cohort is relatively large, we suggest cau-
tion in the generalization of these study findings and the
study of risk factors. However, considering the small size
of the global MDR-TB cohort on treatment [12,13], our
data yields important information regarding ocular
inflammatory disease and ocular tuberculosis among
HIV/MDR-TB patients in a resource-constrained setting.
Third, the diagnosis of choroidal TB was presumptive,
based on characteristic clinical findings. However, the
presence of virtually pathognomonic findings (tubercles)
in the context of systemic TB, as is the case in the
Mumbai cohort, could be considered adequate for the
diagnosis. The presence of other findings (vasculitis, retin-
itis etc.) is more contentious and may need specific micro-
biological or histopathological confirmation. Fourthly, the
patients in our study were previously diagnosed with
tuberculosis, thus the diagnostic utility of detecting ocular
tuberculosis cannot be analyzed for this cohort.
The detection of ocular inflammatory disease in these
patients has several potential applications. First, a proto-
col that mandates retinal screening of all those present-
ing with low CD4 counts, and at subsequent regular
intervals in certain cases, may help in the early diagnosis
of ocular infections (tuberculosis and other opportunis-
tic infections) as well as assess for drug toxicity
(e.g. linezolid-induced optic neuropathy). Since specialty
ophthalmologic consultation is rarely available in
resource-limited settings [20], we have investigated the
possibility of HIV/AIDS clinicians performing indirect
ophthalmoscopy at the primary care level as part of rou-
tine evaluation for OIs [21], and documented the feasi-
bility of this strategy [22]. In support of this approach,
all 6 cases of ocular TB in this report could have been
detected in the HIV clinic by a trained HIV clinician
performing dilated indirect ophthalmoscopy.
Second, assessment of tubercular healing may act as a
clinical in vivo measure of systemic healing, even as an
in vivo clinical tool for timing antitubercular therapy
cessation, as compared to the current standard “one size
fits all” duration of therapy. Investigating this possibility
will require a prospective study correlating clinical out-
comes with ocular outcomes documented with retinal
photography.
Ophthalmologists will increasingly encounter drug-
resistant forms of TB disease and need to be familiar
with the disease patterns and second and third lines of
anti-TB therapy. Clinicians providing care to MDR-TB
patients co-infected with HIV and public health officials
involved in programs for such patients should be aware
of the ocular manifestations and the implications for
them.
Conclusions
In conclusion, based on our findings, we suggest that
ophthalmological examination should be routinely con-
sidered in HIV patients diagnosed with or suspected to
have MDR-TB, especially in those with extrapulmonary
TB.
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Additional file
Additional file 1: A fundus photo of 40 year old male with HIV 1
and extrapulmonary and pulmonary multidrug resistant
tuberculosis showing a choroidal tubercle close to the optic nerve
head.
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